Agilent Technologies (A)
(Delayed Data from NYSE)
$136.37 USD
-1.12 (-0.81%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $136.35 -0.02 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
A 136.37 -1.12(-0.81%)
Will A be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for A based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for A
Waters (WAT) Boosts Waters Operating Segment With HPLC System
Agilent (A) is Set for Analytica 2024 With Advanced Products
A: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agilent (A) to Bolster DCG Segment With Upcoming Solutions
Agilent (A) Boosts LSAG Segment With Advanced Dilution System
Earnings Growth & Price Strength Make Agilent Technologies (A) a Stock to Watch
Other News for A
TechTarget's Enterprise Strategy Group Adds Industry Veteran Jim Frey to Lead Networking Coverage, Research and Analysis
Danaher gains as Q1 results exceed expectations
Dividend Champion, Contender, And Challenger Highlights: Week Of April 21
PacBio cut to Neutral at Goldman Sachs after guidance cut
Analysts Offer Insights on Healthcare Companies: Agilent (A), GlaxoSmithKline (GSK) and Stryker (SYK)